Baxter International Inc. (BAX) CEO Joe Almeida on Q1 2022 Results - Earnings Call Transcript

Baxter International Inc. (NYSE:BAX) Q1 2022 Results Conference Call April 28, 2022 8:30 AM ET

Company Participants

Clare Trachtman - VP, IR

Joe Almeida - Chairman, CEO

Giuseppe Accogli - COO

Jay Saccaro - CFO

Conference Call Participants

Drew Ranieri - Morgan Stanley

Danielle Antalffy - SVB Leerink

Joanne Wuensch - Citi

Larry Biegelsen - Wells Fargo

Matt Miksic - Credit Suisse

Pito Chickering - Deutsche Bank

Robbie Marcus - JP Morgan

Travis Steed - Bank of America

Vijay Kumar - Evercore ISI

Operator

Good morning, ladies and gentlemen, and welcome to Baxter International's First Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's pression. If you have any objections, please disconnect at this time.

I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.

Clare Trachtman

Good morning, and welcome to our first quarter 2022 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; Jay Saccaro, Baxter's Chief Financial Officer; Giuseppe Accogli, Baxter's Chief Operating Officer; and Jim Borzi, Baxter's Chief Supply Chain Officer.

On the call this morning, we will be discussing Baxter's first quarter 2022 financial results and full year financial outlook for 2022. On the call this morning, we will be discussing Baxter's first quarter 2022 financial results and full year financial outlook for 2022.

With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook for the second quarter and full year 2022, the recent acquisition of Hillrom, new product development, business development and regulatory matters including ones related to the 510(k) review of the NOVUM IQ infusion platform contains forward-looking statements that involve risks and uncertainties. And of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more detail concerning factors that could cause actual results to differ materially.

In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.